Repositioning and development of new treatments for neurodegenerative diseases: Focus on neuroinflammation

Eur J Pharmacol. 2022 Mar 15:919:174800. doi: 10.1016/j.ejphar.2022.174800. Epub 2022 Feb 5.

Abstract

Neurodegenerative disorders, such as Alzheimer's and Parkinson's disease, are characterized by the progressive loss of neuronal cells, resulting in different clinical symptoms according to the affected brain region. Although there are drugs available for the treatment of these diseases, they present relatively low efficacy and are not capable of modifying the course of the disease or stopping its progression. In the field of drug development, drug repurposing could be an interesting strategy to search new therapeutic options against neurodegenerative diseases, since it involves lower costs and time for development. In this review, we discuss the search of new treatments for Alzheimer's and Parkinson's disease through drug repurposing. A focus was given to drugs that modulate neuroinflammation, since it represents a common point among neurodegenerative diseases and has been explored as a target for drug action.

Keywords: Alzheimer; Antidiabetics; Immunomodulators; Non-steroidal anti-inflammatory drugs; Parkinson; Statins.

Publication types

  • Review

MeSH terms

  • Clinical Trials as Topic
  • Drug Evaluation, Preclinical
  • Drug Repositioning
  • Humans
  • Neurodegenerative Diseases / drug therapy*
  • Neuroprotective Agents / therapeutic use*

Substances

  • Neuroprotective Agents